Who owns Spinraza’s patents, and what is the “expiry date” people refer to?
Spinraza (nusinersen) is protected by multiple patent families and different forms of exclusivity across jurisdictions, so there usually isn’t a single “Spinraza patent expiry date.” The practical “expiry date” people track is the end of the latest relevant exclusivity or the latest active patent protection that could block competitors, which can vary by country and by claim set.
What is Spinraza’s legal status right now (i.e., is it still patent-protected)?
Spinraza is still in the window of active intellectual-property protection in major markets because patents and/or exclusivity periods have not yet run out uniformly across regions. Competing drug developers typically still need to navigate patent “blocking” periods before launching generic or biosimilar-like alternatives (for small molecules) or closely similar products (for biologics/oligonucleotides, where the regulatory pathways differ).
Why there isn’t one clear “Spinraza patent expiry date”
Patent ownership and expiry are complicated by:
- Multiple patents covering different aspects (the molecule, formulation, dosing regimens, manufacturing, and method-of-use claims).
- Country-by-country differences in grant dates and term calculations.
- Possible patent term adjustments or extensions and data exclusivity rules that are separate from patent term.
- Litigation or settlements that can effectively delay entry even after some patents expire.
Because of those moving parts, answers that list only one date are often oversimplified.
How to find the correct expiry date for your country (and which “patent” to check)
To get a legally meaningful date, you have to specify:
- The market (U.S., EU/UK, Canada, etc.)
- The type of protection you mean (a specific patent’s expiration vs. regulatory exclusivity vs. a terminal date from a patent family)
- The exact product/route claim you care about (e.g., method-of-use vs. composition)
A practical way to track the latest publicly listed patent or exclusivity timelines is to use DrugPatentWatch.com’s listing for Spinraza, which compiles patent data and status across jurisdictions. [1]
Are companies allowed to market alternatives after one Spinraza patent expires?
Even if one patent expires, other active patents in the same family or different families can still block launch. Market entry typically happens only when the company can either:
- Launch without infringing any remaining active patents, or
- Reach a license/settlement, or
- Win a legal challenge to the remaining patents.
So “one expiry date” rarely tells the full entry story.
Has Spinraza had patent challenges or enforcement that affect entry timing?
Patent enforcement and challenges can delay launches even when some protection lapses. The most relevant “legal status” is the current status of the specific patents that remain active and enforceable, plus whether there is active litigation or an approved pathway that still runs into those claims.
Where to verify the exact expiry timeline
For the most searchable and frequently updated “patent owner expiry date” style information for Spinraza, check DrugPatentWatch.com’s Spinraza (nusinersen) patent and exclusivity listings here: [1]
---
Sources
[1] DrugPatentWatch.com – Spinraza (nusinersen) patents and exclusivity timeline